MRNA
Moderna
Biological Products, (No Diagnostic Substances) · Health Care
$228.44+3.45%
Quote via Yahoo Finance, may be delayed · 2026-11-03 · 4:00 PM ET
Daily prices: Yahoo Finance, split-adjusted. As of 2026-11-03.
Drag across the line to read a price. Dots mark earnings, filings and dividends.
Very weak profile
12-1 month return lifts this profile the most.
As of 2025-12-31. Latest quarter ended 2026-06-30. v1 methodology, subject to change.
The profile score is 4 points higher since last quarter. Price is 19 points lower. Profits is 3 points lower.
Sector rank 44 of 46
In plain English
- Moderna operates in Biological Products, (No Diagnostic Substances).
- Latest-year revenue was 1.9 billion.
- The profile score is 30, a Very weak profile. Momentum is the strongest listed input.
Written from the figures on this page. No language model was called. It may still be wrong. Not advice.
As of 2025-12-31. Latest quarter ended 2026-06-30. SEC EDGAR companyfacts, fetched 2026-11-01. SEC filing
Financials
Tap a column to read the value.
P/E vs own history
Not shown while earnings are negative.
Earnings
Actual earnings per share from EDGAR filings. Historical estimates are not used.
Actual from EDGAR
Data confidence
The Company Score summarises financial characteristics relative to similar companies using a published formula. It does not predict future returns.
SEC EDGAR companyfacts, fetched 2026-11-01.